Atopic Dermatitis: Insights, Issues (Do Calcineurin Inhibitors Cause Cancer?), and Integrated Management
A supplement to Pediatric News supported by an educational grant from Novartis. This supplement was jointly sponsored by the Center for Advanced Medical Education, an ACCME accredited provider, and Pediatric News.
The presentations from which this supplement was developed took place at a symposium held October 7, 2005, in Washington, DC.
To view the supplement, click the image above. To take the CME test, download and print out the PDF file, and follow the test instructions on page 15.
Faculty
Introduction
Seth J. Orlow, MD, PhD
Samuel Weinberg Professor of Pediatric Dermatology
Professor of Dermatology, Cell Biology and Pediatrics
Vice Chair for Research, Dermatology
Director of Pediatric and Adolescent Dermatology
New York University School of Medicine
New York Received Honoraria for Speaking: Astellas Pharma Inc. and Novartis Pharmaceuticals Corporation.
Received Honoraria for Consulting: Novartis Pharmaceuticals Corporation.
He has disclosed that he will be discussing unlabeled/unapproved uses of drugs or medical devices.
What is Atopic Dermatitis?
Mary W. Chang, MD
Associate Professor, Dermatology and Pediatrics
University of Connecticut School of Medicine
Chief, Pediatric Dermatology
Connecticut Children's Medical Center
Hartford Received Honoraria for Speaking: Astellas Pharma Inc., Novartis Pharmaceuticals Corporation, and Medicis Pharmaceutical Corporation.
She has disclosed that she will not be discussing unlabeled/unapproved uses of drugs or medical devices.
Pathogenesis of Atopic Dermatitis: Why Does it Happen? What Makes it Worse?
Mark Boguniewicz, MD
Professor, Division of Allergy-Immunology
Department of Pediatrics
National Jewish Medical and Research Center
Professor, Department of Pediatrics
University of Colorado School of Medicine
Denver Received Research Grants as an Investigator: Astellas Pharma Inc. and Novartis Pharmaceuticals Corporation.
Received Honoraria for Speaking: Astellas Pharma Inc. and Novartis Pharmaceuticals Corporation.
He will be discussing unlabeled/unapproved uses of drugs or medical devices.
Topical Corticosteroids and Calcineurin Inhibitors: Safety and Efficacy in Children
Seth J. Orlow, MD, PhD
Perspective on Cancer Risk Associated With Topical Calcineurin Inhibitors
Thomas G. Gross, MD, PhD
Gordon Teter Chair for Pediatric Cancer
Associate Professor, Department of Pediatrics
The Ohio State University
Columbus He has no relevant financial relationships with any commercial interests and will not be discussing unlabeled/unapproved uses of drugs or medical devices.
An Integrated Approach to the Long-Term Management of Atopic Dermatitis
Michael D. Tharp, MD
Clark W. Finnerud, MD, Professor, Chairman and Program Director
Department of Dermatology
Rush University Medical Center
Chicago Received Research Grants as an Investigator: Abbott Laboratories, Astellas Pharma Inc., Biogen Idec Inc., Genentech, Inc., Genmab A/S, and Therakos, Inc.
Received Honoraria for Speaking: Astellas Pharma Inc., Novartis Pharmaceuticals Corporation and Pfizer Inc.
Received Honoraria for Participating in Advisory Boards: Genentech, Inc., and Novartis Pharmaceuticals Corporation.
He will be discussing unlabeled/unapproved uses of drugs or medical devices.
Target Audience
This activity has been developed for pediatricians, pediatric nurses, and other health care professionals who are involved in the diagnosis and management of infants and children with atopic dermatitis.
Educational Needs
Atopic dermatitis (AD), the most common type of eczema, can be a chronic, life-altering skin condition. It affects nearly 15 million Americans. In 90% of people, AD develops before age 5. In fact, nearly 20% of school-age children have the disease. In 40% to 60% of these individuals, AD persists beyond puberty and into adulthood. Although there is currently no cure, various interventions exist to control symptoms. This supplement will provide physicians and other health care professionals who care for infants and children with AD a greater understanding of the extent of the clinical problem; the differential diagnosis of AD; the pathogenesis of AD, including the role of allergens and irritants; and the benefits and risks of current topical therapies for AD. In the last article, this supplement will outline an integrated approach to the long-term management of infants and children with AD.
Learning Objectives
By reading and studying this supplement, participants should be able to:
• identify the skin lesions that are characteristic of AD and differentiate them from other common skin disorders.
• describe the role of allergens and irritants in AD and help patients/parents understand how to avoid them.
• list the two main classes of topical therapies available for patients with AD and summarize their benefits and risks.
• outline and communicate specific strategies for the long-term management of individual patients with AD.
Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Center for Advanced Medical Education and Pediatric News. The Center for Advanced Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Center for Advanced Medical Education designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
